NCT05049265

Clinical Study of JS007 in Patients With Advanced Solid Tumors

A Phase Ia Study to Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single-dose and Multiple-dose Of JS007 Injection In Patients With Advanced Solid Tumors

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 42 (estimated)
• Sponsor: Shanghai Junshi Bioscience Co., Ltd. · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is an open label, phase Ia clinical study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamic (PD) profile, immunogenicity and preliminary efficacy of JS007 in the patients with advanced solid tumors who have progressed after standard of care, or lack of effective standard therapeutic regimen. This study is divided into two periods: dose escalation period, dose expansion period.

Conditions

• Patients With Advanced Solid Tumors

Interventions

Type	Name	Description
BIOLOGICAL	JS007	JS007 only

Timeline

• Start date: 2021-11-17
• Primary completion: 2022-09-20
• Completion: 2022-09-20
• First posted: 2021-09-20
• Last updated: 2021-11-23

Locations

1 site across 1 country: China